Leishmaniasis country profile — 2015 (Published Dec. 2017)

India



COUNTRY GENERAL INFORMATION (WHO, 2015)


Total population:				1,300,000,0	000			
Gender F/M (%):				48.5 / 51.5				
Population, age group <15/ ≥15 years (%):				29 / 71				
Life expectancy at birth (F/M, years) (2015):				70 / 67				
GDP (PPP int \$):				6,050				
Income status:				Lower mid	dle			
Number of 3 rd sub-national administrative level divisions, name	:			6612*, Bloc		te electro la la che silla ance		
	* https://data.gov.in/catalog/number-districts-drdas-blocks-villages- country#web_catalog_tabs_block_10							
EPIDEMIOLOGY	VL		CL		PKDL	MCL		
Endemicity status:	Enden	nic	Endemi	0	Endemic	Non endemic		
Number of new cases (incidence):	8,500		No data	ı	648	N/A		
Number of relapse ¹ cases:	No da	ita	No data	r	N/A	N/A		
Total number of cases:	8,500		No data	I	648	N/A		
Imported cases (#, %):	0,0%		No data	ı	N/A	N/A		
Gender distribution (% F):	39		No data	r	N/A	N/A		
Age group distribution (%, < 5/5-14/>14):	(4/27/	53)	No data	1	(1/20/76)	N/A		
Incidence rate (cases/10,000 population in endemic areas):	0.62		No data	1	N/A	N/A		
Number of endemic 3 rd sub-national administrative level divisions:	603		No data	1	N/A	N/A		
Population at risk ² (%, $\#$ at risk/total population):	10%	136,482,825/ 1,300,000,000	No data	1	N/A	N/A		
Was there any outbreak?	Yes		Unknow	'n	N/A	N/A		
Number of new ³ foci:	No da	ita	No data	1	N/A	N/A		

N/A = Not applicable; 1 Relapse in this country is defined for VL as: "VL: Reappearance of signs and symptoms in a treated patient confirmed by parasite demonstration"; ² Defined as "Number of people living in 3rd sub-national administrative level endemic areas"; ³ Defined as "In this reporting period, an area at the 3rd sub-national administrative level reporting cases for the first time ever".


Monthly distribution of new cases (January-December)

2015	JAN	FEB	MAR	APR	MAY	JUN	JUL	AUG	SEP	OCT	NOV	DEC
VL	496	806	861	887	827	806	754	633	902	519	417	554
CL	No data											

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis




Incidence rate/10,000 (at the national level) and number of new cases from 1998 to 2015



Disease distribution of new VL cases at block level per 10,000 population (2015)

Visceral leishmaniasis



www.who.int/leishmaniasis/Map-VL-India-2015.png

The boundaries and names shown and the designations used on these maps do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. Map production: WHO/HTM/NTD/IDM

CONTROL AND SURVEILLANCE

Year Leishmaniasis National Control Programme (LNCP) was established:	1992
Type of surveillance:	Vertical
Is there a vector control programme?	Yes
Type of insecticide used for Indoor residual Spraying (IRS):	DDT, Synthetic Pyrethroids
Year latest national guidelines:	2015
Is leishmaniasis notifiable (mandatory report)?	Yes
Is there a reservoir host control programme?	Yes
Number of leishmaniasis health facilities:	611

DIAGNOSIS	VL	CL	PKDL	MCL
Number of people screened actively for:	No data	No data	N/A	N/A
Number of people screened passively for:	No data	No data	N/A	N/A
Cases diagnosed by RDT* (%, # RDT+/ total VL cases):	No data	N/A	N/A	N/A
Proportion of positive RDT* (%, # RDT+/total RDT):	No data	N/A	N/A	N/A
Cases diagnosed by direct exam* (parasitology) (%, # slides + / total cases):	No data	No data	N/A	N/A
Proportion of positive slides*(%, # slides + / total slides):	No data	No data	N/A	N/A
Cases diagnosed clinically* (%, # clinical cases/ total cases):	No data	No data	N/A	N/A
Proportion of CL cases with lesions equal to or greater than 4cm*:	N/A	No data	N/A	N/A
Proportion of CL cases with 4 or more lesions*(%, # CL cases/ total CL cases):	N/A	No data	N/A	N/A
Percentage of cases with HIV coinfection*:	1% (45/8,500)	N/A	0% (0/648)	N/A

N/A = Not applicable; RDT = rapid diagnostic test; HIV = human immunodeficiency virus.

TREATMENT AND MEDICINES

Is treatment provided for free in the public sector? Yes

Antileishmanial medicines included in the National Medicine List:

Liposomal Amphotericin B, Sodium stibogluconate (SSG), Amphotericin B deoxycholate, Miltefosine

TREATMENT OUTCOME	VL	CL
Proportion of cases treated*(%, # treated cases/ total cases):	94% (7,967/8,500)	No data
Initial cure rate*(%, # cases initially cured /total cases):	No data	No data
Failure rate4(%, # patients with treatment failure /total cases):	No data	No data
Case fatality rate*(%, # patients who died/ total cases):	0.06% (5/8,500)	No data

VL = visceral leishmaniasis; CL = cutaneous leishmaniasis; PKDL= post-kala-azar dermal leishmaniasis; MCL = mucocutaneous leishmaniasis ⁴ Failure in this country is defined as: No definition available.

* These indicators only apply to new cases.



Data source: Ministry of Health, India © WHO, 2017. All rights reserved

Cutaneous leishmaniasis

Not available